All In Biotech

Drug Trial Radar · NCT03739814

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

May 8, 2019

Primary completion

Feb 1, 2027

Study completion Feb 1, 2027

Sponsor

Sponsor type
NIH
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.

Conditions

  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Recurrent B Acute Lymphoblastic Leukemia
  • Refractory B Acute Lymphoblastic Leukemia

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample and cerebrospinal fluid collection

  • BlinatumomabBiological

    Given IV

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Inotuzumab OzogamicinBiological

    Given IV

  • Lumbar PunctureProcedure

    Undergo lumbar puncture

  • PonatinibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: At 1 year
  2. Completion of protocol treatment (cohort 3)Time frame: Up to 10 years

Locations

285 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Active not recruiting

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Suspended

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska · Suspended

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Suspended

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Suspended

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Suspended

  • Anchorage Oncology Centre

    Anchorage, Alaska · Suspended

  • Katmai Oncology Group

    Anchorage, Alaska · Suspended

  • Providence Alaska Medical Center

    Anchorage, Alaska · Suspended

  • Kingman Regional Medical Center

    Kingman, Arizona · Suspended

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Suspended

  • PCR Oncology

    Arroyo Grande, California · Suspended

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Suspended

  • Community Cancer Institute

    Clovis, California · Active not recruiting

  • University Oncology Associates

    Clovis, California · Active not recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Active not recruiting

  • Beebe Medical Center

    Lewes, Delaware · Suspended

  • Beebe South Coastal Health Campus

    Millville, Delaware · Suspended

  • Delaware Clinical and Laboratory Physicians PA

    Newark, Delaware · Suspended

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware · Recruiting

  • Christiana Care Health System-Christiana Hospital

    Newark, Delaware · Suspended

  • Beebe Health Campus

    Rehoboth Beach, Delaware · Suspended

  • TidalHealth Nanticoke / Allen Cancer Center

    Seaford, Delaware · Suspended

  • Christiana Care Health System-Wilmington Hospital

    Wilmington, Delaware · Suspended

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • Holy Cross Hospital

    Fort Lauderdale, Florida · Suspended

  • Jupiter Medical Center

    Jupiter, Florida · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Suspended

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Suspended

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Suspended

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Suspended

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho · Suspended

Showing 40 of 285 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.